Intelligent Bio files FDA 513 submission for fingerprinting drug screening

Intelligent Bio Solutions announced that the Company has filed a 513(g) submission with the United States Food and Drug Administration, FDA, for its Intelligent Fingerprinting Drug Screening Cartridge. The submission will allow Intelligent Bio Solutions to determine the most suitable FDA regulatory pathway as part of the Company’s strategy for expansion into the U.S. market. "This is a significant step that marks the commencement of our expansion into the United States," said Harry Simeonidis, Chief Executive Officer at Intelligent Bio Solutions. "Our goal is to help address the increasing tide of drug abuse challenges by providing a proven, non-invasive, affordable and easy-to-use product that facilitates the broader adoption of drug screening, thereby promoting a safer work environment."